Brian Carley Sells 5,000 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) Director Brian Carley sold 5,000 shares of Medpace stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the sale, the director owned 27,825 shares of the company’s stock, valued at approximately $16,935,129.75. This trade represents a 15.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Medpace Price Performance

NASDAQ:MEDP opened at $620.75 on Friday. The firm has a 50 day simple moving average of $550.16 and a 200-day simple moving average of $492.71. The firm has a market cap of $17.33 billion, a PE ratio of 36.39, a P/E/G ratio of 2.77 and a beta of 1.15. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace’s revenue was up 17.2% compared to the same quarter last year. During the same quarter last year, the business earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. BMO Capital Markets lifted their price objective on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Royal Bank Of Canada increased their target price on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Barclays set a $600.00 price target on Medpace in a report on Thursday, July 23rd. Finally, Mizuho upped their price objective on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $584.18.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace’s latest earnings exceeded expectations, with quarterly EPS of $4.25 versus the $3.98 consensus estimate and revenue of $707.33 million versus $689.51 million expected. Revenue increased 17.2% year over year, while management maintained fiscal 2026 EPS guidance of $17.25 to $17.95. Why Is Medpace Up Since Its Last Earnings Report?
• Neutral Sentiment: Analyst sentiment remains mostly cautious. Three analysts rate Medpace a Buy and 10 rate it Hold, with a consensus price target of $584.18. Several firms raised their targets following the earnings report, but those targets remain below the stock’s recent trading level. Medpace Analyst Ratings and Price Targets
• Negative Sentiment: Several insiders sold shares on August 19–20. CEO August J. Troendle sold 42,783 shares for roughly $26.3 million, reducing his holdings by about 7% across the reported transactions. Directors Brian T. Carley and Fred B. Davenport Jr. sold 5,000 and 7,283 shares, respectively, reducing their positions by approximately 15% and 66%. While insider sales do not necessarily indicate deteriorating fundamentals, the cluster of transactions may weigh on investor sentiment. Medpace Insider Buying and Selling
• Negative Sentiment: Valuation is demanding, with Medpace trading at approximately 36 times earnings and a PEG ratio of 2.73. The stock is also near the upper end of its 52-week range, increasing sensitivity to profit-taking and any slowdown in growth.

Institutional Trading of Medpace

A number of institutional investors and hedge funds have recently made changes to their positions in MEDP. Johnson Financial Group Inc. acquired a new position in Medpace in the second quarter valued at $27,000. Geneos Wealth Management Inc. grew its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Elyxium Wealth LLC acquired a new stake in Medpace during the fourth quarter worth about $30,000. Jones Financial Companies Lllp acquired a new stake in Medpace during the second quarter worth about $30,000. Finally, Allied Private Wealth LLC acquired a new stake in Medpace during the second quarter worth about $31,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.